Nuformix PLC Directorate Change (7253R)
November 09 2021 - 2:00AM
UK Regulatory
TIDMNFX
RNS Number : 7253R
Nuformix PLC
09 November 2021
9 November 2021
The information communicated within this announcement is deemed
to constitute inside information as stipulated under the Market
Abuse Regulations (EU) No. 596/2014. Upon the publication of this
announcement, this inside information is now considered to be in
the public domain.
Nuformix plc
("Nuformix" or the "Company")
Directorate change
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, announces that Dr Alastair Riddell, currently
Non-Executive Chairman, will assume the role of Executive Chairman
with effect from 1 December 2021.
Enquiries:
Nuformix plc via Walbrook
Dr Alastair Riddell, Non-Executive
Chairman
Dr Anne Brindley, CEO
Allenby Capital Limited +44 (0) 20 3328 5656
Nick Athanas / George Payne (Corporate
Finance)
Stefano Aquilino / Matt Butlin (Sales
and Corporate Broking)
Walbrook PR nuformix@walbrookpr.com or +44 (0)20
7933 8780
Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44
(0)7867 984 082
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has an early-stage pipeline of preclinical
and Phase 1-ready assets with potential for significant value and
early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABPBBTMTMMTIB
(END) Dow Jones Newswires
November 09, 2021 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024